Allos Therapeutics Inc - Post-Effective Amendment to an S-8 filing (S-8 POS)
25 6월 2008 - 4:51AM
Edgar (US Regulatory)
As filed
with the Securities and Exchange Commission on June 24, 2008
Registration
No. 333-76804
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
POST-EFFECTIVE
AMENDMENT NO. 1
TO
FORM S-8
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
ALLOS
THERAPEUTICS, INC.
(Exact name of
registrant as specified in its charter)
Delaware
|
|
|
|
54-1655029
|
(State of
Incorporation)
|
|
|
|
(I.R.S. Employer
Identification No.)
|
11080 CirclePoint Road, Suite 200
Westminster, Colorado 80020
(Address of principal executive offices)
2002 Broad Based Equity Incentive Plan
(Full title of the plan)
Paul L. Berns
President and Chief Executive Officer
Allos Therapeutics, Inc.
11080 CirclePoint Road, Suite 200
Westminster, Colorado 80020
(303) 426-6262
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
Copies to:
James C. T. Linfield, Esq.
Brent D. Fassett, Esq.
COOLEY GODWARD KRONISH LLP
380 Interlocken Crescent, Suite 900
Broomfield, Colorado 80021
(720) 566-4000
Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See definitions of
large accelerated filer, accelerated filer and smaller reporting company
in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
o
|
Accelerated filer
x
|
Non-accelerated filer
o
|
Smaller reporting
company
o
|
|
|
(Do not check if a smaller
reporting company)
|
|
DEREGISTRATION
OF UNSOLD SECURITIES
This
Post-Effective Amendment No. 1 to Form S-8 Registration Statement
relates to the Registration Statement on Form S-8 (File No. 333-76804)
(the Registration Statement) of Allos Therapeutics, Inc. (the Company)
pertaining to 1,000,000 shares of the Companys common stock, par value $0.001
per share, which was filed with the Securities and Exchange Commission and
became effective on January 16, 2002.
The Registration Statement registered 1,000,000 shares of common stock
for sale pursuant to the Companys 2002 Broad Based Equity Incentive Plan (the 2002
Plan).
On
June 24, 2008 (the Effective Date), the stockholders of the Company
approved the Companys 2008 Equity Incentive Plan (the 2008 Plan). The 2008 Plan is intended as the successor to
and continuation of the 2002 Plan. As of
the Effective Date of the 2008 Plan, all shares remaining available for
issuance under the 2002 Plan became available for issuance under the 2008 Plan
and all outstanding stock awards granted under the 2002 Plan were deemed
granted pursuant to the 2008 Plan, but remain subject to the terms of the 2002
Plan. As of the Effective Date, no
additional stock awards will be granted under the 2002 Plan. The Company intends to file a new Form S-8
Registration Statement pertaining to the 2008 Plan.
Subject
to the foregoing, and in accordance with an undertaking made by the Company in
the Registration Statement to remove from registration, by means of a
post-effective amendment, any of the securities registered under the Registration
Statement that remain unsold at the termination of the offering, the Company
hereby removes from registration the securities of the Company registered but
unsold under the Registration Statement.
2
SIGNATURES
Pursuant to the
requirements of the Securities Act of 1933, as amended, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Post-Effective
Amendment No. 1 to Registration Statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of Westminster, State
of Colorado, on June 24, 2008.
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
By:
|
/s/ Paul
L. Berns
|
|
|
Paul L. Berns
|
|
|
President and
Chief Executive Officer
|
|
|
|
|
Pursuant to the
requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1
to Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Stephen J.
Hoffman
|
|
Chairman of
Board of
|
|
June 24,
2008
|
(Stephen J.
Hoffman)
|
|
Directors and
Director
|
|
|
|
|
|
|
|
/s/ Paul L.
Berns
|
|
President, Chief
Executive Officer
|
|
June 24,
2008
|
(Paul L. Berns)
|
|
and Director
|
|
|
|
|
(Principal
Executive Officer)
|
|
|
|
|
|
|
|
/s/ David C.
Clark
|
|
Vice President,
Finance and Treasurer
|
|
June 24,
2008
|
(David C. Clark)
|
|
(Principal
Financial Officer and
|
|
|
|
|
Principal
Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Michael D.
Casey
|
|
Director
|
|
June 24,
2008
|
(Michael D.
Casey)
|
|
|
|
|
|
|
|
|
|
/s/ Stewart Hen
|
|
Director
|
|
June 24,
2008
|
(Stewart Hen)
|
|
|
|
|
|
|
|
|
|
/s/ Jeffrey R.
Latts
|
|
Director
|
|
June 24,
2008
|
(Jeffrey R.
Latts)
|
|
|
|
|
|
|
|
|
|
/s/ Jonathan S.
Leff
|
|
Director
|
|
June 24,
2008
|
(Jonathan S.
Leff)
|
|
|
|
|
|
|
|
|
|
/s/ Timothy P.
Lynch
|
|
Director
|
|
June 24,
2008
|
(Timothy P.
Lynch)
|
|
|
|
|
3
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024